ODM 204

Drug Profile

ODM 204

Alternative Names: ODM-204

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Orion
  • Class Antineoplastics
  • Mechanism of Action Androgen receptor antagonists; Steroid 17-alpha-hydroxylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Prostate cancer

Most Recent Events

  • 25 Oct 2016 Orion terminates phase I/II trial in Prostate cancer in United Kingdom, France, Latvia due to unfavourable pharmacokinetic results
  • 17 Dec 2014 Phase-I/II clinical trials in Prostate cancer (Metastatic disease) in Finland (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top